Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.69 -0.01 (-0.00%) Dow
39,055.53 +171.27 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
62,233.47 -755.82 (-1.20%) CMC Crypto 200
1,323.28 +28.61 (+2.21%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous close | 3.9900 |
| Open | 4.0200 |
| Bid | 3.9800 x N/A |
| Ask | 3.9900 x N/A |
| Day's range | 3.9600 - 4.0200 |
| 52-week range | 3.4400 - 9.1000 |
| Volume | |
| Avg. volume | 65,544 |
| Market cap | 141.066M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- CNW Group
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano
- CNW Group
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.
- PR Newswire
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
